SOPHiA GENETICS announced that Bioma4me is now live on the SOPHiA DDM? Platform. The company will use SOPHiA GENETICS' technology to advance and streamline its genetic testing capabilities.

Bioma4me is a leader in Brazil in providing personalized medicine, supported by genetic analysis of each individual, offered at an affordable cost, with great precision and in the shortest possible time. Through the SOPHiA DDM? Platform, Bioma4me will be able to apply its next-generation sequencing (NGS) expertise to the whole exome.

The SOPHiA DDM? Platform will help the company streamline and expedite data analysis, which will save valuable time for clinical researchers and support the enablement of precision medicine for customers. The SOPHiA DDM?

Platform will enable Bioma4me fast turnaround time for results. Additionally, Bioma4me will have full ownership over its data and access to the SOPHiA GENETICSdecentralized global network, helping to continuously advance its researchers' capabilities and knowledge base.